Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crestor Safety Data Under FDA Review; 11 Reports Of Rhabdomyolysis At 10 Mg Dose

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency appears unlikely to make a significant change in the regulatory status of the statin in the near term; FDA notes that most of the reported cases of rhabdomyolysis and renal failure could be attributed to the underlying disease or concomitant medications. Public Citizen renews call for Crestor's withdrawal in Lancet article.

You may also be interested in...



Vytorin Managed Care Outlook More Positive Than Crestor, Survey Finds

Merck/Schering's Zocor/Zetia fixed-dose combo is likely to have coverage in one of the top two tiers in up to 50% of managed care plans six to 12 months post-launch, a Prudential survey finds. Crestor has coverage in top two tiers for about 30% of plans after one year on the market.

Vytorin Managed Care Outlook More Positive Than Crestor, Survey Finds

Merck/Schering's Zocor/Zetia fixed-dose combo is likely to have coverage in one of the top two tiers in up to 50% of managed care plans six to 12 months post-launch, a Prudential survey finds. Crestor has coverage in top two tiers for about 30% of plans after one year on the market.

AstraZeneca Questions Reliability Of Crestor Adverse Event Reports

A Public Citizen petition seeking withdrawal of rosuvastatin is “based on inappropriate and misleading interpretations of selective and incomplete data,” CEO McKillop says. AstraZeneca asserts Crestor’s adverse event profile is similar to other statins.

Related Content

Topics

UsernamePublicRestriction

Register

PS059793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel